The evidence from experimental studies suggests that activators of SIRT1 (resveratrol or oxyresveratrol) and substrate competitive SIRT2 inhibitors are promising candidates for neuroprotective agents beneficial in PD [94,96]. The gene discussed is SIRT1; the disease is Parkinson disease.